Disease relapse most commonly occurs at distant metastatic sites and remains the primary driver of poor outcomes, emphasizing the need for therapies to target drivers of relapse.<h4>Experimental design</h4>This study identified DNA-PKcs as a critical determinant of poor survival and metastatic relapse in neuroblastoma patients. The gene discussed is PRKDC; the disease is neuroblastoma.